Combination Drugs Diagnostic Market

Combination Drugs Diagnostic Market by Products (Steroid-eluting Electrodes, Antimicrobial Catheters, Cardiovascular Catheters, Urological Catheters, Oximetry Catheters, Thermodilution Catheters, Bone Graft Substitutes, Peripheral Vascular Stent, Wound Drainage Catheters, Deep Brain Stimulator, Verteporfin, and Porfimer Sodium), Applications (Respiratory Disorders, Infectious Diseases, Psychiatric Disorders, Cardiovascular Diseases, and Others), End-users (Hospitals, Private Clinics, Physicians, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2657
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 183
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global combination drugs diagnostic market size is expected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growing demand for efficient combination diagnosis facilities and early stage approval of drugs by various regulatory authorities.

Combination Drugs Diagnostic Market key takeaways

A combination drug, often known as a fixed-dose combination (FDC), is a medication that contains two or more active components in one dosage form. Fixed-dose combination medication products were first created to address a single disease such as antiretroviral FDCs for Acquired Immune Deficiency Syndrome (AIDS) treatment. Kaletra, atripla, combivir, truvada, trizivir, symbax, contrave, and excalia, are some of the most popular combination medications available in the market. According to a research published by the World Health Organization (WHO), 14.1% of the global population is estimated to be diagnosed with neurologic disorder by 2020, driving major pharmaceutical companies to develop combination medications during the forecast period.

Due to the outbreak of COVID-19 pandemic, many industries have been impacted for months as it forced to shut the production units globally. Moreover, low demand for instruments and consumables along with the global supply chain interruptions and trade restrictions have harmed the market for few months.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing advanced technology for diagnostics procedures and rising expenditure on R&D activities are key factors up surging the market growth.
  • Systematized dosage helps in improving the effect of combination drugs and improved compliance in the treatment of chronic diseases such as TB and HIV are expected to fuel the market expansion.
  • Rising number of clinical trials and advent of digital diagnostic facilities are anticipated to propel the market growth during the forecast period.
  • High cost involved in manufacturing products affects the market share in low & middle income level countries. This is expected to hamper the market growth in the coming years.
  • Various side effects resulting to low adherence and strict regulatory standards for the licensing of therapy compositions are major challenges that can hamper the market growth.
  • Increasing development in operational expertise by key pharmaceutical companies to improve the laboratory testing are likely to offer immense opportunities for the market development in the long run.

Scope of the Report

The report on the global combination drugs diagnostic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Combination Drugs Diagnostic Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Steroid-eluting Electrodes, Antimicrobial Catheters, Cardiovascular Catheters, Urological Catheters, Oximetry Catheters, Thermodilution Catheters, Bone Graft Substitutes, Peripheral Vascular Stent, Wound Drainage Catheters, Deep Brain Stimulator, Verteporfin, and Porfimer Sodium), Applications (Respiratory Disorders, Infectious Diseases, Psychiatric Disorders, Cardiovascular Diseases, and Others), and End-users (Hospitals, Private Clinics, Physicians, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Zimmer Holding Inc.; Smith & Nephew plc; Biometrix Medical; Medtronic Inc.; Stryker Corp.; Boston Scientific Corp.; St. Jude Medical Inc.; Merck & Co.; Wright Medical Group Inc.; Roche Diagnostics; Abbott Laboratories; Novartis AG; Bristol Myers Squibb; Arrow International Inc.; IntegraLifeSciences Holding Corp.; Covidien Ltd.; DePuy Orthopaedics Inc.; Angiotech Pharmaceuticals Inc.; Biomet Orthopaedics Inc.; and Cordis Corp.

 

Market Segment Insights

Antimicrobial catheters segment is expected to grow at a rapid pace

Based on products, the global combination drugs diagnostic market is segregated as steroid- eluting electrodes, antimicrobial catheters, cardiovascular catheters, urological catheters, oximetry catheters, thermodilution catheters, bone graft substitutes, peripheral vascular stent, wound drainage catheters, deep brain stimulator, verteporfin, and porfimer sodium. The antimicrobial catheters segment is expected to grow at a rapid pace during the forecast period owing to the growing awareness level related to antimicrobial agents, cost-effective treatment, and rising cases of infections.

Moreover, the antimicrobial-coated catheters segment is projected to account for a large market share during the forecast period as it reduces the risk of hospitalization, catheter-associated urinary tract infections (CAUTIs) or nosocomial urinary tract infections by preventing the formation of biofilms and crust. Furthermore, the growth of the segment is attributed to the emerging new applications implemented by pharmaceutical manufacturers globally to develop unique catheter products and technological advancements in catheter devices, with the goal of reducing the 2 million infections contracted by hospital patients each year.

Infectious disease segment is projected to expand at a considerable CAGR

On the basis of applications, the market is segmented into respiratory disorders, infectious diseases, psychiatric disorders, cardiovascular diseases, and others. The infectious disease segment is projected to expand at a considerable CAGR during the forecast period due to the prevalence of infectious diseases in developed and developing regions. The rising number of prescriptions for infectious disease diagnostic tests and the efficient diagnosis management of such disorders combined with the growing tendency toward preventative care, are projected to fuel the segment growth.

Combination Drugs Diagnostic Market by applications

Hospital segment is estimated to gain a large market share

Based on end users, the global combination drugs diagnostic market is divided into hospitals, private clinics, physicians, and others. The hospital segment is estimated to gain a large market share in the coming years as hospitals are the important part of the healthcare industry and a key source of revenue for the overall industry, which stimulates research and innovation. Hence, a number of firms offer large amount of resources to promote their products and services among hospitals, both in terms of revenue and marketing tactics. Furthermore, strategic decisions made in the hospital sector can have an impact on other sectors of the healthcare industry, providing them significant control over contract conditions with the service providers. Thus, cumulatively all these factors are propelling the segment growth.

Combination Drugs Diagnostic Market by end users

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the growing number of research and development activities, availability of advanced & innovative products, increasing cases of cardiovascular diseases & diabetes, and encouraging government policies. Furthermore, the US Food and Drug Administration (FDA) has permitted Opdivo injection for intravenous use along with increasing demand for combination drugs directed the manufacturers to provide the market with novel drugs. Thus, these factors are expected to boost the market expansion in the region in the coming years.

Segments

The global combination drugs diagnostic market has been segmented on the basis of

Products

  • Steroid-eluting Electrodes
  • Antimicrobial Catheters
  • Cardiovascular Catheters
  • Urological Catheters
  • Oximetry Catheters
  • Thermodilution Catheters
  • Bone Graft Substitutes
  • Peripheral Vascular Stent
  • Wound Drainage Catheters
  • Deep Brain Stimulator
  • Verteporfin
  • Porfimer Sodium

Applications

  • Respiratory Disorders
  • Infectious Diseases
  • Psychiatric Disorders
  • Cardiovascular Diseases
  • Others

End-users

  • Hospitals
  • Private Clinics
  • Physicians
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Zimmer Holding Inc.
  • Smith & Nephew plc
  • Biometrix Medical
  • Medtronic Inc.
  • Stryker Corp.
  • Boston Scientific Corp.
  • St. Jude Medical Inc.
  • Merck & Co.
  • Wright Medical Group Inc.
  • Roche Diagnostics
  • Abbott Laboratories
  • Novartis AG
  • Bristol Myers Squibb
  • Arrow International Inc.
  • IntegraLifeSciences Holding Corp.
  • Covidien Ltd.
  • DePuy Orthopaedics Inc.
  • Angiotech Pharmaceuticals Inc.
  • Biomet Orthopaedics Inc.
  • Cordis Corp.

Competitive Landscape

Some of the key players competing in the global combination drugs diagnostic market are Zimmer Holding Inc.; Smith & Nephew plc; Biometrix Medical; Medtronic Inc.; Stryker Corp.; Boston Scientific Corp.; St. Jude Medical Inc.; Merck & Co.; Wright Medical Group Inc.; Roche Diagnostics; Abbott Laboratories; Novartis AG; Bristol Myers Squibb; Arrow International Inc.; IntegraLifeSciences Holding Corp.; Covidien Ltd.; DePuy Orthopaedics Inc.; Angiotech Pharmaceuticals Inc.; Biomet Orthopaedics Inc.; and Cordis Corp.

To obtain an advantage over their competitors, companies are implementing marketing strategies such as collaboration, regional expansions, promotional activities, and new product development. For instance, Bristol Myers Squibb partnered with Seattle Genetics in January 2015 to conduct a clinical trial to calculate the investigational combination of Bristol Myers' immunotherapy Opdivo and Seattle Genetics' antibody-drug conjugate Adcetris.

Combination Drugs Diagnostic Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Combination Drugs Diagnostic Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Combination Drugs Diagnostic Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Combination Drugs Diagnostic Market - Supply Chain
  4.5. Global Combination Drugs Diagnostic Market Forecast
     4.5.1. Combination Drugs Diagnostic Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Combination Drugs Diagnostic Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Combination Drugs Diagnostic Market Absolute $ Opportunity
5. Global Combination Drugs Diagnostic Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Combination Drugs Diagnostic Market Size and Volume Forecast by Applications
     5.3.1. Respiratory Disorders
     5.3.2. Infectious Diseases
     5.3.3. Psychiatric Disorders
     5.3.4. Cardiovascular Diseases
     5.3.5. Others
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Combination Drugs Diagnostic Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Combination Drugs Diagnostic Market Size and Volume Forecast by End Users
     6.3.1. Hospitals
     6.3.2. Private Clinics
     6.3.3. Physicians
     6.3.4. Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Combination Drugs Diagnostic Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Combination Drugs Diagnostic Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Combination Drugs Diagnostic Demand Share Forecast, 2019-2026
8. North America Combination Drugs Diagnostic Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Combination Drugs Diagnostic Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Combination Drugs Diagnostic Market Size and Volume Forecast by Applications
     8.4.1. Respiratory Disorders
     8.4.2. Infectious Diseases
     8.4.3. Psychiatric Disorders
     8.4.4. Cardiovascular Diseases
     8.4.5. Others
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. North America Combination Drugs Diagnostic Market Size and Volume Forecast by End Users
     8.7.1. Hospitals
     8.7.2. Private Clinics
     8.7.3. Physicians
     8.7.4. Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Combination Drugs Diagnostic Demand Share Forecast, 2019-2026
9. Latin America Combination Drugs Diagnostic Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Combination Drugs Diagnostic Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Combination Drugs Diagnostic Market Size and Volume Forecast by Applications
     9.4.1. Respiratory Disorders
     9.4.2. Infectious Diseases
     9.4.3. Psychiatric Disorders
     9.4.4. Cardiovascular Diseases
     9.4.5. Others
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Latin America Combination Drugs Diagnostic Market Size and Volume Forecast by End Users
     9.7.1. Hospitals
     9.7.2. Private Clinics
     9.7.3. Physicians
     9.7.4. Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Combination Drugs Diagnostic Demand Share Forecast, 2019-2026
10. Europe Combination Drugs Diagnostic Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Combination Drugs Diagnostic Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Combination Drugs Diagnostic Market Size and Volume Forecast by Applications
     10.4.1. Respiratory Disorders
     10.4.2. Infectious Diseases
     10.4.3. Psychiatric Disorders
     10.4.4. Cardiovascular Diseases
     10.4.5. Others
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Europe Combination Drugs Diagnostic Market Size and Volume Forecast by End Users
     10.7.1. Hospitals
     10.7.2. Private Clinics
     10.7.3. Physicians
     10.7.4. Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Combination Drugs Diagnostic Demand Share Forecast, 2019-2026
11. Asia Pacific Combination Drugs Diagnostic Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Combination Drugs Diagnostic Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Combination Drugs Diagnostic Market Size and Volume Forecast by Applications
     11.4.1. Respiratory Disorders
     11.4.2. Infectious Diseases
     11.4.3. Psychiatric Disorders
     11.4.4. Cardiovascular Diseases
     11.4.5. Others
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Asia Pacific Combination Drugs Diagnostic Market Size and Volume Forecast by End Users
     11.7.1. Hospitals
     11.7.2. Private Clinics
     11.7.3. Physicians
     11.7.4. Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Combination Drugs Diagnostic Demand Share Forecast, 2019-2026
12. Middle East & Africa Combination Drugs Diagnostic Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Combination Drugs Diagnostic Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Combination Drugs Diagnostic Market Size and Volume Forecast by Applications
     12.4.1. Respiratory Disorders
     12.4.2. Infectious Diseases
     12.4.3. Psychiatric Disorders
     12.4.4. Cardiovascular Diseases
     12.4.5. Others
  12.5. Basis Point Share (BPS) Analysis by Applications
  12.6. Y-o-Y Growth Projections by Applications
  12.7. Middle East & Africa Combination Drugs Diagnostic Market Size and Volume Forecast by End Users
     12.7.1. Hospitals
     12.7.2. Private Clinics
     12.7.3. Physicians
     12.7.4. Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Combination Drugs Diagnostic Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Combination Drugs Diagnostic Market: Market Share Analysis
  13.2. Combination Drugs Diagnostic Distributors and Customers
  13.3. Combination Drugs Diagnostic Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Zimmer Holding Inc.
     13.4.2. Smith & Nephew plc
     13.4.3. Biometrix Medical
     13.4.4. Medtronic Inc.
     13.4.5. Stryker Corp.
     13.4.6. Boston Scientific Corp.
     13.4.7. St. Jude Medical Inc.

The global combination drugs diagnostic market has been segmented on the basis of

Products

  • Steroid-eluting Electrodes
  • Antimicrobial Catheters
  • Cardiovascular Catheters
  • Urological Catheters
  • Oximetry Catheters
  • Thermodilution Catheters
  • Bone Graft Substitutes
  • Peripheral Vascular Stent
  • Wound Drainage Catheters
  • Deep Brain Stimulator
  • Verteporfin
  • Porfimer Sodium

Applications

  • Respiratory Disorders
  • Infectious Diseases
  • Psychiatric Disorders
  • Cardiovascular Diseases
  • Others

End-users

  • Hospitals
  • Private Clinics
  • Physicians
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Zimmer Holding Inc.
  • Smith & Nephew plc
  • Biometrix Medical
  • Medtronic Inc.
  • Stryker Corp.
  • Boston Scientific Corp.
  • St. Jude Medical Inc.
  • Merck & Co.
  • Wright Medical Group Inc.
  • Roche Diagnostics
  • Abbott Laboratories
  • Novartis AG
  • Bristol Myers Squibb
  • Arrow International Inc.
  • IntegraLifeSciences Holding Corp.
  • Covidien Ltd.
  • DePuy Orthopaedics Inc.
  • Angiotech Pharmaceuticals Inc.
  • Biomet Orthopaedics Inc.
  • Cordis Corp.

Some of the key players competing in the global combination drugs diagnostic market are Zimmer Holding Inc.; Smith & Nephew plc; Biometrix Medical; Medtronic Inc.; Stryker Corp.; Boston Scientific Corp.; St. Jude Medical Inc.; Merck & Co.; Wright Medical Group Inc.; Roche Diagnostics; Abbott Laboratories; Novartis AG; Bristol Myers Squibb; Arrow International Inc.; IntegraLifeSciences Holding Corp.; Covidien Ltd.; DePuy Orthopaedics Inc.; Angiotech Pharmaceuticals Inc.; Biomet Orthopaedics Inc.; and Cordis Corp.

To obtain an advantage over their competitors, companies are implementing marketing strategies such as collaboration, regional expansions, promotional activities, and new product development. For instance, Bristol Myers Squibb partnered with Seattle Genetics in January 2015 to conduct a clinical trial to calculate the investigational combination of Bristol Myers' immunotherapy Opdivo and Seattle Genetics' antibody-drug conjugate Adcetris.

Combination Drugs Diagnostic Market by key players

Buy Report